- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trialLi, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Wu, Lingying被引 21
- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trialLi, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Banerjee, Ashish; Wu, Lingying
- First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter studyLi, J.; Youguo, C.; Mian, H.; Chen, X.; Wen, H.; Kang, Y.; Liu, K. J.; Lou, G.; Wang, X.; Wen, Q. L.; Wang, L.; Lin, Z.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagnosed advanced ovarian cancer (aOC)
2阅读
